Comment trouver des profils ? Plus d'infos

Aide

« Retour

Charmet Jérôme

Professeur-e HEs ordinaire

Compétences principales

Professeur-e HEs ordinaire

Haute Ecole Arc - Ingénierie
Espace de l'Europe 11, 2000 Neuchâtel, CH

Professeur HES Associé A, Groupe Dispositif Médicaux, Haute Ecole Arc, HES-SO, CH

Adjunct Professor, School of Biomedical and Precision Engineering, Bern Universität, CH

Professeur Associé Honoraire, Warwick Medical School, University of Warwick, UK

Haute Ecole Arc

Eplatures Grises 17
2300 La Chaux-de-Fonds

Switzerland

BSc HES-SO en Microtechniques - Haute Ecole Arc - Ingénierie

MSc in Biomedical Engineering - Universität Bern

En cours

Bacterial Suicide

Rôle: Requérant(e) principal(e)

Financement: HES-SO

HYPERCELL

Rôle: Requérant(e) principal(e)

Financement: FNS - Health and Wellbeing call

Description du projet:

Adoptive T cell therapy (aTcT) is a highly promising type of immunotherapy used to treat several malignancies. This type of therapy is particularly promising for non-small cell lung cancer (NSCLC), the deadliest cancer worldwide. However, its efficacy remains very low. In addition, like many other immunotherapies, aTcT is expensive, not effective for every patient and may have serious side-effects.

Therefore, there is a need for fast, personalized and minimally disruptive assays to measure the efficacy of adoptive T cell therapy, which is our main objective.

The project is split in two distinct specific objectives:

1) Development and validation of a single device, called the HYPERCELL chip that will allow for the evaluation of the efficacy of autologous adoptive-cells therapy at the single cell level. The unique chip will be composed of a re-usable control module, a disposable liquid biopsy assay and cytotoxicity assay modules, to deliver a simple, fast and minimally disruptive assay.

2) Study and understanding process-dependent shear stress and its effect on cell viability and function ex vivo. The insights gained from this study will be applicable to a wide range of assays, beyond the HYPERCELL project itself.

By providing an integrated solution that allows for seamless evaluation of T cells therapies on patients derived cells, the HYPERCELL chip has the potential to improve their outcomes. Indeed, this device that will be self-contained relies on existing laboratory workflows and equipment, it is therefore expected to be easily adopted in clinical environment.

Equipe de recherche au sein de la HES-SO: Charmet Jérôme

Partenaires académiques: Cleo Goyvaerts, VUB, Belgium; Alexandre Kuhn, HES-SO Valais

Durée du projet: 01.10.2024 - 30.09.2027

Montant global du projet: 1'010'261 CHF

Statut: En cours

ELUSIVE

Rôle: Requérant(e) principal(e)

Financement: HES-SO

DNAMIC

Rôle: Co-requérant(s)

Requérant(e)s: Ignas Galminas, Genomika, LT

Financement: H2020 - EIC Pathfinder

Description du projet:

We live in a society that produces and requires more and more data every year. It has become apparent that our current data storage strategies are not adequate to meet this increasing demand.

The quest for robust, high-density, sustainable, and economically viable data storage solutions has highlighted the enormous potential and suitability of DNA data storage.

However, to date, none of the solutions have considered a comprehensive vision of anchoring this technology in standardised archival frameworks that will support long-term storage. Besides, most DNA data storage applications are limited to specialist laboratories due to complex (and expensive) protocols.

Our project entitled DNAMIC (DNA Microfactory for Autonomous Archiving) proposes an autonomous solution based around a low energy consumption microfactory that will be developed for end-to-end DNA data archiving (from encoding to decoding via synthesis, storage, quality control and sequencing among others).

The microfactory is interoperable and future proof thanks to technology block that can be easily modified or replaced. Our solution will be compliant with the Open Archival Information System (OAIS) reference model (ISO 14721). To enable the implementation of disaster recovery strategies, critical for long term storage, we propose a novel dual-level encoding scheme. This approach allows the development of self-contained data that include easily changeable metadata, and unalterable data.

Equipe de recherche au sein de la HES-SO: Charmet Jérôme , Neuenschwander Patrick , Serex Florian , Beurret Stéphane , Remonnay Valentin , Salvadé Yves , Angeloni Suter Silvia , Wenger Samuel , Béguin Vincent

Partenaires académiques: Fritz Simmel, TUM, DE; Thomas Heinis, Imperial College, UK; Renaldas Raisutis, KTU, LT; Pierre-Yves Burgi, Université de Genève

Partenaires professionnels: Ignas Galminas, Genomika, LT; Martin Jost, Kilobaser, Mabeal, AT

Durée du projet: 01.10.2023 - 30.09.2026

Montant global du projet: 4'951'890 CHF

Url du site du projet: https://dnamic.org

Statut: En cours

BiModal Sensor

Rôle: Co-requérant(s)

Requérant(e)s: Ender Yildirim, METU, Turkey

Financement: TUBITAK

Public Mask

Rôle: Co-requérant(s)

Financement: HES-SO

Terminés

Misc projets

Rôle: Requérant(e) principal(e)

Description du projet:

Projets de recherche en tant que Professeur Associé à l'Université de Warwick.

(total > £2 mio. entre 2016-2021 en tant qu’investigateur principal)

• Feeling the force: Enhancing OOAC capability for biomechanical assessment and application. UK Research and Innovation (Co-investigateur, £23k), mars 2021.
• Organ-on-chip platform for TEER imaging, UK Research and Innovation (£30k), janvier 2021.
• Capacity Building for Prototyping Compatible Injection Moulding, High Value Manufacturing (£236k, trois partenaires industriels), mars 2020.
• Identification of metastatic biomarkers in nasopharyngeal carcinoma (NPC) to improve clinical management, Global Challenges Research Fund, (Co-investigateur, £50k), décembre 2019.
• MICRA Commercialisation Development Grant Award (£19k, deux partenaires industriels), dé-cembre 2019.
• Engineering Cardiovascular Systems using Protein Scaffolds, Monash-Warwick Alliance, Acceler-ator project (£247k), juillet 2019.
• Blood-brain-barrier on a chip to study the clinical relevance of circadian timing of anticancer drugs. Royal Society RGS\R2\180434 (£19k), mars 2019.
• Microfabrication suite. Capital Award for ECR. Engineering and Physical Science Research Coun-cil (EPSRC) EP/S017887/1 (£80k), janvier 2019.
• PleuSense, Differential diagnosis of pleural effusion, Institutional Links grant, ID 352360246, under the Newton-Katip Celebi Fund partnership, (£288k, deux partenaires industriels), février 2018.
• mPatch, mobile device for fitness and health monitoring. High Value Manufacturing Catapult (£213k, deux partenaires industriels), octobre 2017.
• Integrated platform with MEMS cantilever for the early detection of prostate cancer using dry mass sensing. EPSRC EP/R00403X/1 (£126k, un partenaire industriel), octobre 2017.
• Diamond Light Source beamtime, Beamline B22, B23 (67 shifts, ~£580k, deux partenaires indus-triels), depuis mars 2017.
• Mandats Industriels (£205k), depuis janvier 2017.
• University of Warwick; Research development fund, Global Fund partnership, Global Research Priority (total: £40k), depuis mars 2017.

Equipe de recherche au sein de la HES-SO: Charmet Jérôme

Durée du projet: - 14.02.2022

Montant global du projet: 2'500'000 CHF

Statut: Terminé

2026

Dynamic bacterial growth modulation in structurally distinct and functionally tuneable agarose hydrogels

Article scientifique ArODES

Andrea Dsouza, Dylan Taylor, Christopher Parmenter, Rachel A. Hand, Julia Brettschneider, Meera Unnikrishnan, Chrystala Constantinidou, Jérôme Charmet

Communications Materials, 2026, To be published.

PEOPLE@HES-SO Annuaire et Répertoire des compétences

Charmet Jérôme

Professeur-e HEs ordinaire

Compétences principales

Biosensors

Sample Processing

Microfluidics

Advanced Manufacturing

Functional materials

Professeur-e HEs ordinaire

PEOPLE@HES-SO
Annuaire et Répertoire des compétences